Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 G1, BASi Sign Preferred Provider Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

G1, BASi Sign Preferred Provider Pact

BASi to provide preclinical services to support G1 programs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BASi has entered into a Preferred Provider Agreement with G1 Therapeutics for preclinical services, including toxicology, bioanalytical and analytical testing, to support G1’s drug development programs. G1 is a privately held company that develops small molecule therapeutics to protect bone marrow from damage due to chemotherapy or radiation.
 
BASi’s president, chief executive officer, and chief financial officer, Jacqueline M. Lemke, said, “With our common focus on innovation and scientific excellence, this PPA is a natural arrangement for both of our companies. We are proud that G1 recognizes the ability of BASi’s research team to conduct studies which generate quality and timely data, a critical part of the drug development process.”
 
“BASi has been a valuable partner as we advance our lead clinical candidate toward IND filing and clinical development,” said Jay Strum, Ph.D., chief scientific officer and president, G1 Therapeutics. “We look forward to working with BASi to complete a number of pre-clinical activities necessary for the IND filing in 2014.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics